UCLA CTSI Director, Steven Dubinett, MD, participated in the 11th Annual American Association for Cancer Research (AACR) Frontiers in Cancer Prevention Research International Conference and discussed the advantages of the CTSI during his educational session on “The Clinical and Translational Science Award Program: Transdisciplinary Teams in Cancer Prevention Research” on Tuesday, October 16th.
Navigating the NIH K Award Process - Carol Mangione, MD, MSPH (2022)
10/16 AACR Team Science Presentation
1. The Clinical and Translational Science Award Program:
Transdisciplinary Teams
in Cancer Prevention Research
11th Annual International
Conference on Frontiers in
Cancer Prevention Research
October 16, 2012
Steven Dubinett, MD
Director, Clinical and Translational Science Institute
Senior Associate Dean and Associate Vice Chancellor for Research, UCLA
www.ctsi.ucla.edu
2. Disclosure Information
11th Annual International Conference on Frontiers in Cancer Prevention Research
The Clinical and Translational Science Award Program:
Transdisciplinary Teams in Cancer Prevention Research
Steven Dubinett
I have no financial relationships to disclose.
– and –
I will not discuss off label use and/or investigational use in my presentation.
3. National, regional and institutional teams
National CTSA
Program
CTSA Constoria
Team Science
4. Purpose of the
National CTSA Program
Providing an infrastructure for clinical and
translational research
OLD NEW
Inpatient
GCRC Outpatient & community based research
Individual
investigators Transdisciplinary team science
Traditional Training in clinical and translational
training
team science
Individual
academic
Regional and national consortia
medical centers linked for collaboration
6. UCLA CTSI
Clinical and Translational Science Institute
Team Science-
How do we get there?
• Facilitate - infrastructure
• Reward - funding
• Recognize - promotions
• Training - in the team environment
www.ctsi.ucla.edu
7. CTSI Research Funding
• Pilot Program: 53 awards totaling $1.8 million
• Team Science Awards: up to $200K for team science
proposals
• Core Services Vouchers: awards of up to $10K each
• Business of Science Center collaborations: fellowships
and team awards
• CTSI Scholars: mentored research program for new
faculty; $30K each annually
• Shared Resources Consortium: support for
instrumentation and existing and proposed cores 7
8. Current Team Science Award
Partners
• AIDS Institute
• Jonsson Comprehensive Cancer Center
• Broad Stem Cell Research Center
• Cardiovascular
• Neuroscience
• Patient Safety Institute (PSI)
• Center for AIDS Research (CFAR)
8
9. Current Seed Grant Partners
• Center for Autism Research & Treatment (CART)
• Cousins Center for Psychoneuroimmunology
• Women’s Health Center
• Resource Centers for Minority Aging Research /
Center for Health Improvement for Minority
Elders (RCMAR/CHIME)
• Pepper Center
9
10. Examples of Team Science Awards
Barbara Vickrey, MD, MPH
Stroke/cardiovascular disease in underserved minority
populations:
• working with community partners, design and test
interventions to reduce risk of disease
Joel Braslow, MD, PhD
DMH-UCLA-USC Public Mental Health Translational
Research Consortium:
• in partnership with LA County and USC, implement best
practices within the public mental health system
Antoni Ribas, MD
Overcoming acquired resistance to B-Raf targeting in
melanoma using phospho-proteomics and microfluidics:
• Building a comprehensive program for signaling
discovery and diagnostics to guide kinase inhibitor 10
clinical trials in melanoma
11. Clinical and Translational Research
Center (CTRC)
Ambulatory Clinical Research Facilities
• 7 private rooms, infusion rooms, 2 procedure rooms
• >20,000 sq ft outpatient area
• Clinical and Research Sleep Center
• Interview and conference rooms
• A service center including
pharmacy and sample processing
• 23 hour capacity
First Year accomplishments
400 ongoing research projects
80 new protocols
4800 out-patient
& 210 in-patient stays
12. What is translational research?
UCLA translational investigation extends
from molecules to society
Translating knowledge gained from laboratory
science into clinical practice to improve health.
The aim of translational research is to produce
new:
• therapeutics
• medical devices
• tools for diagnosing disease
• community engagement research/ implementation 12
14. UC BRAID
University of California - Biomedical Research,
Acceleration, Integration & Development
a new initiative…
building on success of 5 CTSAs
http://www.ucbraid.org/
15. UC Biomedical Research Acceleration
Integration and Development (UC-BRAID)
• A committee of the CTSA PIs at UC Davis,
San Diego, San Francisco, Irvine and Los
Angeles
• contracting, informatics and IRBs
• Drug discovery and development
• Biobanking and global consent
• Future inclusion of other partner institutions
15
20. Science of Team Science
• growing interest and investment in large-
scale, team-based research initiatives to
address complex and multi-faceted
problems that require cross-disciplinary
collaboration
•The science-of-team-science field -
concerned especially with understanding
and managing circumstances that facilitate
or hinder the effectiveness of team science
initiatives. Stokols, Am J Prev Med 2008
23. Changes in Bronchial Epithelium in Relation to Cigarette
Smoking and in Relation to Lung Cancer
Oscar Auerbach, A. P. Stout, E. Cuyler Hammond, and Lawrence Garfinkel
NEJM August 10, 1961
Rui Li Paul Pagano Jeannette Grant Kostyantyn Krysan Elvira Liclican Tonya Walser Felicita Baratelli
Gina Lee Stacy Park Brian Gardner Puja Kachroo Ying Lin Wen Mao Zhe Jing 23
24. Two Models of Cancer Development and Progression
Model 1 Model 2
normal normal
tissue tissue
(e.g., a stem cell
expressing Snail) metastasis
in situ
cancer dissemination
DNA damage
disseminated in situ
cancer cancer
DNA damage
aggressive
aggressive disseminated metastasis
metastasis cancer
Adapted from Sánchez-García NEJM 2009
25. Snail drives programs of inflammation, migration/invasion,
angiogenesis and stem cell phenotype expansion in HBEC
Snail in Premalignancy
Squamous
AAH Metaplasia
Air-Liquid Interface 3D Model
HBEC-
Vector Q-RT-PCR
H&E Snail E-cad Ki67 Validation
HBEC-
Snail
27. Which features of pulmonary premalignancy
portend transformation and progression?
Squamous
AAH Metaplasia
What proteins/genes are evident
in situ in premalignancy?
…and which are critical for
driving transformation and
progression?
Air-Liquid Interface 3D Model
HBEC-
Vector
H&E Snail E-cad Ki67
HBEC-
Snail
28. Team Science
Tonya Walser Maie St. John Avi Spira (Boston University)
Kostyantyn Krysan Xiaoyan Cui Marc Lenburg (Boston University)
David Elashoff Saswati Hazra Ignacio Wistuba (MD Anderson)
Leonard Rome Elvira Liclican Pierre Massion (Vanderbilt)
Jay Lee Eileen Heinrich Jerry Shay (UT Southwestern)
Edward Garon Jie Luo John Minna (UT Southwestern)
Gina Lee Wen Mao Patient advocates &
Fran Rosen Ying Lin foundations
Sherven Sharma Zhe Jing
Minu Srivastava Li Zhu
Felicita Baratelli Yuan Lin
Ying Lin Stacy Park
Mi-Heon Lee Jeanette Grant
Michael Fishbein Nicole Rodriguez
Dean Wallace Paul Pagano
Denise Aberle Rui Li
Fereidoun Abtin Sahil Patel
Robert Suh Puja Kachroo
Brian Gardner Aik Ooi
Brigitte Gomperts Dorthe Shaue
Min Huang Grigoriy Shekhtman
Supported by:
NCI EDRN · Lung Cancer SPORE · VA · DOD · LungEVITY · UCLA CTSI ·
Tobacco Related Disease Res Program · Broad Foundation · LCMC